Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14959657 | 0.85 | PTGS2 (0.53) | PTGS2PTGS1SLC6A4 | |
| SCHEMBL13814624 | 0.76 | HTT (0.63) | PTGS2PTGS1HTTSMN1; SMN2TDP1 | |
| SCHEMBL2758531 | 0.76 | HTT (0.63) | PTGS2PTGS1HTTSMN1; SMN2TDP1 | |
| SCHEMBL14667733 | 0.75 | KDM4E (0.47) | HTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL21486338 | 0.72 | TEAD4 (0.45) | HTTSMN1; SMN2TDP1L3MBTL1SLC6A4 | |
| SCHEMBL23153426 | 0.72 | HTT (0.73) | PTGS2PTGS1HTTSMN1; SMN2TDP1 | |
| SCHEMBL2758532 | 0.72 | PTGS2 (0.58) | PTGS2PTGS1HTTSMN1; SMN2TDP1 | |
| SCHEMBL20149706 | 0.72 | PTGS2 (0.58) | PTGS2PTGS1HTTSMN1; SMN2TDP1 | |
| SCHEMBL12708896 | 0.72 | PTGS2 (0.58) | PTGS2PTGS1HTTSMN1; SMN2TDP1 | |
| SCHEMBL19105488 | 0.72 | HTT (0.73) | PTGS2PTGS1HTTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130144056-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120071653-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7989661-B2 | Human ADAM-10 inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20100105953-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-7629341-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. (US) | 2009-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | PTGS2 93/4885PTGS1 161/4885HTT 4650/4885 |
| US-20120071653-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | PTGS2 651/4885PTGS1 167/4885HTT 2138/4885 |
| US-20100105953-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | PTGS2 651/4885PTGS1 167/4885HTT 2138/4885 |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | PTGS2 64/4885PTGS1 102/4885HTT 4364/4885 |
| US-20130144056-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | PTGS2 651/4885PTGS1 167/4885HTT 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.